4.6 Article

Inflammation and Ectopic Fat Deposition in the Aging Murine Liver Is Influenced by CCR2

Journal

AMERICAN JOURNAL OF PATHOLOGY
Volume 190, Issue 2, Pages 372-387

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajpath.2019.10.016

Keywords

-

Categories

Funding

  1. NIH [R01-AG055564, R01-DK103645, F31-DK112633, U24-DK059637, P30-DK020593]
  2. Cellular Approaches to Tissue Engineering and Regeneration T32 training grant [T32-EB001026]
  3. Pittsburgh Liver Research Center Pilot and Feasibility Award [P30-DK120531]

Ask authors/readers for more resources

Aging is associated with inflammation and metabolic syndrome, which manifests in the liver as nonalcoholic fatty liver disease (NAFLD). NAFLD can range in severity from steatosis to fibrotic steatohepatitis and is a major cause of hepatic morbidity. However, the pathogenesis of NAFLD in naturally aged animals is unclear. Herein, we performed a comprehensive study of lipid content and inflammatory signature of livers in 19-month-old aged female mice. These animals exhibited increased body and liver weight, hepatic triglycerides, and inflammatory gene expression compared with 3-month-old young controls. The aged mice also had a significant increase in F4/80(+) hepatic macrophages, which coexpressed CD11b, suggesting a circulating monocyte origin. A global knockout of the receptor for monocyte chemoattractant protein (CCR2) prevented excess steatosis and inflammation in aging livers but did not reduce the number of CD11b(+) macrophages, suggesting changes in macrophage accumulation precede or are independent from chemokine (C-C motif) ligand-CCR2 signaling in the development of age-related NAFLD. RNA sequencing further elucidated complex changes in inflammatory and metabolic gene expression in the aging liver. In conclusion, we report a previously unknown accumulation of CD11b(+) macrophages in aged livers with robust inflammatory and metabolic transcriptomic changes. A better understanding of the hallmarks of aging in the liver will be crucial in the development of preventive measures and treatments for end-stage liver disease in elderly patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available